Abstract

This presentation describes the new fixed-dose antimalarial formulation ASMQ (artesunate + mefloquine) and its advantages in terms of ease of use, efficacy and tolerability (as well as contraindications); reasons why it needs further study in Africa are given.

Citation

Presentation from ‘The ASMQ Fixed-Dose Combination to treat Malaria: From Blueprint to Use in the Field’. Symposium from American Society of Tropical Medicine and Hygiene 58th Annual Meeting, Washington, DC, USA, 19 November 2009.

The ASMQ - FDC.

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.